Palliative percutaneous radiotherapy in non-small-cell lung cancer

Budach, Wilfried; Belka, Claus

doi:10.1016/j.lungcan.2004.07.969

Cited by 15 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total dose of 60 Gy in 30 fractions is the current recommended dose for stage II/III receiving concurrent chemoradiation. For stage IV NSCLC disease, a regimen of 30 Gy in 10 daily fractions is typically used for palliative treatment [14]. While using this dose regimen does initially relieve symptoms, it may not have a sustained effect.…”

Section: Prt Based On Histology and Stagementioning

confidence: 99%

“…A definitive dose of radiation with combined chemotherapy may also be acceptable for patients with good performance and limited distant disease (such as solitary brain metastasis). There is limited evidence showing that higher dose thoracic radiation is associated with extension of survival in patients with good performance status [14].…”

Section: Prt Based On Histology and Stagementioning

confidence: 99%

See 1 more Smart Citation

Personalized Radiation Therapy (PRT) for Lung Cancer

Jin

Kong

2015

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

This chapter reviews and discusses approaches and strategies of personalized radiation therapy (PRT) for lung cancers at four different levels: (1) clinically established PRT based on a patient's histology, stage, tumor volume and tumor locations; (2) personalized adaptive radiation therapy (RT) based on image response during treatment; (3) PRT based on biomarkers; (4) personalized fractionation schedule. The current RT practice for lung cancer is partially individualized according to tumor histology, stage, size/location, and combination with use of systemic therapy. During-RT PET-CT image guided adaptive treatment is being tested in a multicenter trial. Treatment response detected by the during-RT images may also provide a strategy to further personalize the remaining treatment. Research on biomarker-guided PRT is ongoing. The biomarkers include genomics, proteomics, microRNA, cytokines, metabolomics from tumor and blood samples, and radiomics from PET, CT, SPECT images. Finally, RT fractionation schedule may also be personalized to each individual patient to maximize therapeutic gain. Future PRT should be based on comprehensive considerations of knowledge acquired from all these levels, as well as consideration of the societal value such as cost and effectiveness.

show abstract

Section: Prt Based On Histology and Stagementioning

confidence: 99%

Section: Prt Based On Histology and Stagementioning

confidence: 99%

Personalized Radiation Therapy (PRT) for Lung Cancer

Jin

Kong

2015

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

show abstract

“…Nach einem aktuellen systematischen Review (13 randomisierte, kontrollierte Studien, 3 473 Patien− ten) ist von einer vergleichbaren Symptomkontrolle mit etwas erhöhter Akuttoxizität der Kurz− zeitschemata auszugehen, gegen die die Behandlungsbelastung (Transport, Lagerung) bei den Langzeitkonzepten abzuwägen ist [35]. Patienten in schlechtem Allgemeinzustand (Karnofsky− Index unter 70 %) profitieren in Bezug auf Gesamtüberleben und Symptomlinderung nicht von der höheren Gesamtdosis bei konventioneller Fraktionierung [36,37]. Schlussfolgernd wird empfohlen, dass diese Patienten mit 2 7,5 Gy oder 5 4 Gy bestrahlt werden sollen.…”

Section: Einzelne Hirnmetastasenunclassified

Palliative Strahlentherapie

Oorschot¹,

Rades²,

Schulze³

et al. 2009

Palliativmedizin

View full text Add to dashboard Cite

“…quality of life metrics and survival. Numerous studies have been done and are well summarized in three systematic reviews [46][47][48]. There is randomized data demonstrating a modest survival benefit with increases in total dose, for e.g.…”

Section: Lung Palliationmentioning

confidence: 99%